MD prompts federal action on pharmacy oversight after meningitis outbreak
State health officials don't know how often Marylanders use medications mixed in facilities lacking safety oversight, like a Massachusetts facility linked to three deaths here, but a newly passed law could tell them — and help demonstrate a gap in federal regulation. Batches of sterile drugs from so-called compounding pharmacies will be subject to state review under the measure Gov. Martin O'Malley signed this month. And pharmacists and doctors who perform compounding, in which drugs are somehow altered from their Food and Drug Administration-approved form, will face an extra layer of permits and inspections for drugs used in Maryland. But "it's not realistic for Maryland to set up national oversight," said Joshua M. Sharfstein, the state health secretary.
- mHealth Tackles Readmissions
- 'Kafkaesque' Value System Unfairly Penalizes Doctor Pay
- CNO Leads $1M Charge for New Scrubs, Uniforms
- Targeting Self-Insured Populations
- MA an Insurance Proving Ground for Providers
- Proton Beam Therapy Poised for Growth in US
- Sharp HealthCare Leaves Pioneer ACO Program
- Some Cancer Hospitals' Quality Data Will Soon Be Public
- Half of All Primary Care, Internal Medicine Jobs Unfilled in 2013
- Docs Fret as HHS Addresses Malpractice Reporting 'Loopholes'